BioSpace News Archive

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the comparative bioavailability, pharmacokinetics, and safety of its oral betamethasone spray, GTX-102, compared to an intramuscular injection of betamethasone and to an oral solution of betamethasone, in 48 healthy subjects.

Locus Biosciences, Inc. announced that the ELIMINATE trial has begun enrolling patients and the first patient has been treated. ELIMINATE is a registration-enabling Phase 2/3 clinical trial of lead candidate LBP-EC01.

Second Fast Track designation for efzofitimod clinical program.

AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, announced that chairman and CEO Hans Keirstead, Ph.D., will deliver a keynote address at AI for Good, a program dedicated to achieving the United Nations Sustainable Development Goals through practical AI applications.

Suneva Medical, Inc. (“Suneva” or the “Company”) today launched the 30 mL iteration of their Amplifine Platelet Rich Plasma (PRP) gel tubes, which will provide patients and practices with a larger volume of PRP to address varying areas of concern more efficiently.

Momentis Surgical™ Ltd, a medical device company dedicated to transforming surgery with its proprietary surgical robotic technology, today announced that Lee Health has acquired the Anovo™ Surgical System, the first and only FDA-authorized surgical robot with features designed to mimic human arms and provide human level dexterity.

Turn Biotechnologies today announced it has created a novel platform to safely and effectively deliver nucleic acid therapeutics – a major expansion of the company’s business.

RayzeBio, Inc. today announced significant progress in clinical development of its lead product candidate, RYZ101. RYZ101 is an investigational, targeted radiopharmaceutical drug designed to deliver Actinium-225 (Ac225), a highly potent alpha-emitting radioisotope, to solid tumors expressing the somatostatin receptor (SSTR).

Nascent Biotech, Inc. announced today the completion of the Fourth Cohort in dosing patients in the Company’s Phase I trial to evaluate Pritumumab as a treatment for Brain Cancer, including Primary and metastatic Brain Tumors.

Otsuka America Pharmaceutical, Inc., (Otsuka) and H. Lundbeck A/S (Lundbeck) announce the U.S. Food and Drug Administration (FDA) acceptance of their New Drug Application (NDA) for aripiprazole 2-month, ready-to-use, long-acting injectable, a medication administered for the treatment of schizophrenia in adults and for maintenance monotherapy treatment of bipolar I disorder in adults.